Keyphrases
Hemophilia
100%
Bleeding
33%
Severe Haemophilia A
32%
Hemophilia Patients
25%
Nonacog beta Pegol
25%
BAY 94-9027
24%
Acquired Hemophilia A
20%
Immune Response
17%
Annualized Bleeding Rate
14%
Von Willebrand Factor
13%
Factor VIII (FVIII)
13%
PEGylated
13%
CD4+ T Cells
12%
Inhibitor Development
11%
Coagulation Factor VIII
11%
Extended Half-life Factor VIII
11%
Haemophilia Treatment Centre
10%
Von Willebrand Disease
10%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
10%
Clotting Factors
10%
Recombinant
10%
Congenital Hemophilia
10%
Recombinant Activated Factor VII (rFVIIa)
10%
Recombinant Factor VIII
10%
Factor VIII Inhibitor
9%
Extended Half-life
9%
Long-term Safety
8%
Long-term Efficacy
8%
B Domain
7%
Epitope
7%
Anticoagulation
7%
Activated Partial Thromboplastin Time (aPTT)
7%
Bleeding Symptoms
7%
Pharmacokinetics
7%
CD4 Cells
7%
Median Range
6%
Valoctocogene Roxaparvovec
6%
Product Reviews
6%
On-demand Treatment
6%
Twice Daily
6%
CD4+
5%
Joint Bleeding
5%
Quality of Life
5%
Gene Therapy
5%
B-domain Deleted Recombinant Factor VIII
5%
Acute Bleeding
5%
Surgical Procedures
5%
Clinical Trials
5%
Clinical Practice Guidelines
5%
Bleeding Episodes
5%
Medicine and Dentistry
Haemophilia A
53%
Bleeding
32%
Blood Clotting Factor 8
19%
Ciclonicate
12%
Patient with Hemophilia
11%
Recombinant Blood Clotting Factor 7a
11%
Observational Study
10%
Recombinant Blood Clotting Factor 8
10%
Von Willebrand Factor
10%
Arthropathy
8%
Bleeding Disorder
8%
Quality of Life
7%
Anticoagulation
7%
Clinical Trial
7%
Von Willebrand Disease
6%
Hemostat
6%
Infusion
5%
Adverse Event
5%
Immunological Tolerance
5%
Surgical Technique
5%
Blood Clotting Factor
5%
